Leo Pharma's US sales organization waited 8 months on approval: "It has had an economic impact"

Since spring, 133 Leo Pharma sales representatives have been at the ready to send tralokinumab to the US market. The wait has been spent on selling other products and learning from the eczema drug's launches in Europe. On Tuesday, the US approval finally arrived.

While Becki Morison, executive vice president responsible for Global Therapeutic & Value Strategy at Leo Pharma, is disappointed over the 8-month delay of tralokinumab, the wait has also had some benefits | Photo: Leo Pharma/PR

When the US Food and Drug Administration (FDA) approved of Leo Pharma's drug, tralokinumab, as a treatment for atopic dermatitis, the Danish firm's entire US-based sales organization was ready to push the launch button. 

Leo Pharma was originally expecting the approval in April but was instead met with an FDA rejection, as the authority required additional data pertaining to a device component of the eczema injection.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs